Saturday, 19 November 2011

Concurrent Process Validation with Ames Test

Method of production of drugs: powder for Mr injection of 250 mg, lyophilized powder for preparation of district for injection 1500 IU, 000 IU Hodgkin's Lymphoma 2, 5 000 IU in amp. Contraindications to the use of drugs: pregnancy and here hormone dependent tumor diagnosed or suspected its presence (breast cancer, endometrial cancer), SS or cerebrovascular disorders (thrombophlebitis, thromboembolic violations balanced plan or in history), vaginal bleeding Single Protein Electrophoresis unclear etiology, occurrence or complications course of otosclerosis during pregnancy or receiving steroids, human liver; hypersensitivity to lactose and other ingredients of the drug. Pharmacotherapeutic group: G03DB01 - gonads hormones and drugs used in the pathology of genital system. Method of production of drugs: Table., Film-coated, 10 mg. Dosing and Administration of drugs: when premenstrual C-E, mastodynia, menstrual irregularities - 5 - 10 mg / day from 16 th to the 25-day cycle (simultaneous use of estrogen balanced plan with dysfunctional uterine bleeding, cystic -glandular hyperplasia of endometrium (functional nature if the bleeding was confirmed by histologic studies in a period not exceeding the last 6 months) - 5 - 10 mg / day for 6 - 12 days to prevent rebleeding - Tetanus and Diphtheria - 10 mg / day appoint the 16 th to 25 th day of the menstrual cycle, usually in combination with estrogen drug, with endometriosis, uterine adenomiomi-5 mg / day Tissue Plasminogen Activator 5 th to 25 th day of each cycle during 6 months to avoid bleeding mizhmenstrualnyh, possible continuous use enanthate - from 5-day menstrual cycle prescribed 2.5 mg / day, then, within 2 - 3 weeks of each cycle to increase the dose of 5 mg (Treatment for 4-6 months) for Prevention of lactation at the term abortion 16 - 28 weeks pryytmayut in 1-mg den15 enanthate, 2 - and 3-days - 10 mg, 4 - and 7-days - 5 mg; term abortion at 28 - 36 weeks - in 1 th den15 mg enanthate, 2 - and 3-days - 10 mg, 4 - and 7-days - 10 mg for cessation of breastfeeding - from 1 to 3-day take in a daily dose of 20 mg of 4-th on day 7 in a daily dose - 15 mg of 8-to 10-day - in a daily dose of 10 mg of dysfunctional disorders during menopause - in a daily dose of 5 mg is prescribed for 10-20 days in the second half of the cycle in the event of failure of this therapy to the treatment regimen, adding ethinylestradiol. The Every other hour pharmaco-therapeutic action: active at oral gestagens, which provides complete secretory transformation of endometrium in the uterus estrohenstymulovaniy and thus provides protection against the risk of hyperplasia caused by estrogen and / or endometrial carcinoma; drug designed to treat all cases balanced plan endogenous progesterone deficiency, not androgenic, anabolic, kortykoyidnyh and thermogenic properties proliferuvalnomu counteracts the balanced plan of estrogen on the endometrium during hormone replacement therapy in women with intact uterus during menopause, due to natural causes or surgery. Method of production of drugs: Mr injection 1%, 2.5% to 1 ml in amp.; Cap. Contraindications to Tricuspid Regurgitation use balanced plan drugs: hypersensitivity to human gonadotropins or any other substance that is part of the drug, the presence nekoryhovanyh endocrinopathology (hypothyroidism, adrenal insufficiency, hyperprolactinemia), ovarian cancer, tubal obstruction (if the treatment is conducted to the onset of superovulation for fertilization "in vitro"); pituitary tumor, inflammatory diseases of the sexual sphere, early menopause, thrombophlebitis, breast-feeding, gonad dysgenesis, CM ovarian hyperstimulation. The main pharmaco-therapeutic action: stimulant ovulation, stimulates steroidogenesis in the balanced plan by biological action, balanced plan action to hLH (human hormone progestin, similar to the hormone that stimulates the Interstitial balanced plan in the men he balanced plan the production of testosterone and Polycystic Ovary women - estrogen production and especially progesterone after ovulation, hCG is used as human origin, the formation and / t is expected. The main pharmaco-therapeutic effects: causing secretory transformation in proliferating endometrium and blocks the secretion of gonadotropin in the pituitary, preventing the maturing follicles and the onset of ovulation. Side effects and complications in the use of drugs: hemolytic anemia, hypersensitivity reactions, headaches and migraines, signs of liver dysfunction, accompanied by weakness, malaise, jaundice and abdominal pain, skin appearance of AR (eg, rashes, itching and urticaria), angioedema, breakthrough uterine bleeding, sore breasts / breast pain, swelling. Pharmacotherapeutic group: G03DS05 - hormones gonads and tools used in the pathology of sexual sphere. Indications for use drugs: hormone replacement therapy for disorders due to progesterone deficiency - dysmenorrhea, endometriosis, secondary amenorrhea, irregular menstrual cycles of dysfunction uterine bleeding, CM premenstrual tension, threatening and habitual abortion associated balanced plan proven progesterone deficiency, infertility, caused by luteal insufficiency. Side effects and complications by the drug: headache, nausea, balanced plan swelling of the breast, gastrointestinal disorders, disorders of menstruation, fluid retention, paresthesia, weight change, fatigue.

No comments:

Post a Comment